Metformin, placebo, and endocrine therapy discontinuation among participants in a randomized double-blind trial of metformin versus placebo in hormone receptor–positive early-stage breast cancer (CCTG MA32).

Authors

Dawn L. Hershman

Columbia University College of Physicians and Surgeons, New York, NY

Dawn L. Hershman , Bingshu E. Chen , Wendy R. Parulekar , Julie Lemieux , Jennifer A. Ligibel , Karen A. Gelmon , Timothy Joseph Whelan , Pamela Jean Goodwin

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2018 ASCO Annual Meeting

bookmark_border

CA15-3/MUC1 in CCTG MA-32 (NCT01101438): A phase III RCT of the effect of metformin vs. placebo on invasive disease free and overall survival in early stage breast cancer (BC).

First Author: Ryan JO Dowling

insert_chart_outlined

Poster

2013 ASCO Annual Meeting

bookmark_border

Effect of metformin versus placebo on weight and metabolic factors in initial patients enrolled onto NCIC CTG MA.32, a multicenter adjuvant randomized controlled trial in early-stage breast cancer (BC).

First Author: Pamela Jean Goodwin

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Pharmacological cardioprotective strategy for non-metastatic patients affected by breast cancer receiving an anthracycline-based chemotherapy: Final results of the phase 3 SAFE trial.

First Author: Lorenzo Livi

insert_chart_outlined

Poster

2019 ASCO Quality Care Symposium

bookmark_border

“I had already made up my mind.” The impact of prior experience and health care perceptions on decision making in women with early-stage breast cancer.

First Author: Rebecca England